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We analyzed blood samples from infants born with micro-
cephaly and their mothers in Guinea-Bissau in 2016 for 
pathogens associated with birth defects. No Zika virus RNA 
was detected, but Zika virus IgG was highly prevalent. We 
recommend implementing pathogen screening of infants 
with congenital defects in Guinea-Bissau.
In 2016, the health authorities in Guinea-Bissau reported 4 cases of Zika virus infection and 5 cases of microceph-
aly (1) to the World Health Organization. The Zika virus 
strain detected in Guinea-Bissau was the African strain 
(1) originally detected in Africa in 1947 and in Portuguese 
Guinea (now Guinea-Bissau) during 1964–1965 (2). As of 
March 2018, the Asian strain, which has spread throughout 
the Americas and Cape Verde (2) and is linked to micro-
cephaly and other congenital abnormalities, has not been 
reported in Guinea-Bissau (3), and the African Zika virus 
strain has not been linked with microcephaly.
We report an in-depth investigation of pathogens com-
monly associated with birth defects in 15 infants born with 
microcephaly in Guinea-Bissau in 2016. Field epidemi-
ologists identified cases of microcephaly through reports 
from health center personnel across the country and sur-
veillance at Hospital Nacional Simão Mendes in Bissau, 
Guinea-Bissau (which has 6,000 births/y). Most cases were 
found in the northern and eastern regions (Gabú, Bafatá, 
and Oio) of Guinea-Bissau (online Technical Appendix 
Tables 1, 2, https://wwwnc.cdc.gov/EID/article/24/5/18-
0153-Techapp1.pdf). Blood samples were collected from 
the mothers (median age 22 years, range 15–31 years) and 
infants (median age 5 months, range 1 day–9 months) and 
sent to Statens Serum Institut (Copenhagen, Denmark) for 
analysis. Three infants died before sampling, and 1 sample 
was lost during transport; hence, we analyzed blood sam-
ples from 11 of the 15 infants with microcephaly. For com-
parison, we also analyzed blood samples from 10 mothers 
(from Tantam Cossé, Bafatá region) of infants born without 
microcephaly (M.W. Rosenstierne, unpub. data). We as-
sayed for Zika virus and TORCH pathogens (Toxoplasma 
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gondii, other [Treponema pallidum, varicella-zoster virus, 
parvovirus B19], rubella virus, cytomegalovirus [CMV], 
and herpes simplex virus) (online Technical Appendix 
Tables 1, 2) because these pathogens are most commonly 
associated with congenital anomalies (4,5).
Zika virus IgG immunofluorescence assay and Zika 
virus neutralization test (6,7) results revealed that 14 (93%) 
of the 15 mothers of infants with microcephaly had Zika 
virus neutralizing antibodies (NAbs) (online Technical 
Appendix Tables 1, 2) versus 5 (50%) of the 10 mothers 
of healthy infants (data not shown). We tested blood sam-
ples from the 11 infants with microcephaly for Zika virus 
NAbs, and all were positive (presumably maternal antibod-
ies) (online Technical Appendix Tables 1, 2). We did not 
perform this assay with samples from the healthy infants. 
No samples were positive for Zika virus RNA or IgM or 
had cross-neutralizing antibodies to dengue virus. Thus, the 
Zika virus seroprevalence among Guinea-Bissau women 
was surprisingly high and significantly higher in the moth-
ers of infants with birth defects (p = 0.02 by Fisher exact 
test). However, timing of the Zika virus infection and strain 
could not be determined.
Because of sample volume limitations, we tested only 
10 of 15 mothers for TORCH antibodies and all 11 infants 
with birth defects and available blood samples for TORCH 
pathogen nucleic acids (online Technical Appendix Tables 
1, 2). Four infant blood samples were positive for CMV 
DNA and IgG but only 2 were positive for CMV IgM (on-
line Technical Appendix Tables 1, 2). Two of these infants’ 
mothers were CMV IgG positive (the other 2 were not test-
ed), and 1 mother tested positive for CMV IgM. Because 
sampling of infants was mainly performed 5 months post-
partum rather than during the first 2–3 weeks postpartum 
(5,8), determining whether the CMV infections were con-
genital or acquired perinatally or postnatally (e.g., through 
breast milk) was not possible.
The mother whose infant died 5 days after birth was 
positive for Toxoplasma IgG (online Technical Appendix 
Tables 1, 2). However, samples from this child were not 
collected for analysis, so we could not determine whether 
the infant died of severe congenital toxoplasmosis. As 
expected, almost all mothers were positive for antibodies 
against parvovirus (70%), varicella-zoster virus (90%), 
rubella virus (90%), CMV (90%), and herpes simplex vi-
rus (100%).
Although we found a high prevalence of Zika virus 
NAbs and TORCH antibodies in mothers and infants, the 
late sampling of infants and lack of Zika virus RNA–posi-
tive samples precludes determination of the cause of micro-
cephaly in these infants. On the basis of our findings, we 
propose implementing prospective surveillance in Guinea-
Bissau for infants with easily identifiable congenital abnor-
malities, such as microcephaly (i.e., head circumference 
2 standard deviations below average for age and sex) (9), 
microphthalmia, and hearing loss, and screening these in-
fants for Zika virus and TORCH by using blood, saliva, 
and urine samples collected immediately or within the first 
2–3 weeks after birth. The low prevalence (0.6%) of micro-
cephaly reported in 2015 (10) makes this suggestion feasi-
ble in resource-poor countries. If the Asian Zika virus strain 
is detected in Guinea-Bissau, screening of pregnant women 
during their first trimester should also be implemented. 
However, the 2-step surveillance and screening model can 
be applied in countries without reported detection of the 
Asian Zika virus strain.
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To the Editor: We read with interest the article by 
Furuya-Kanamori et al. on the proportion of influenza vi-
rus infections that are asymptomatic or subclinical (1), and 
we are troubled by a series of fundamental flaws and er-
rors. We were concerned that the authors presented pooled 
estimates of the asymptomatic fraction, given the massive 
heterogeneity in estimates (Ι2 values of 97%–98% in Table 
1). It is not considered good practice to present pooled es-
timates in instances of massive heterogeneity (2). We were 
very surprised that the authors included volunteer challenge 
studies because it is well known that the severity of these 
infections can be modulated by the route of administration 
and possibly the infectious dose. We also were surprised 
that human infections with avian influenza viruses were in-
cluded because the epidemiology of these infections differs 
markedly from that of human influenza viruses. These stud-
ies were mistakenly labeled as studies of pandemic influen-
za in online Technical Appendix 1 Table 1 (https://wwwnc.
cdc.gov/EID/article/22/6/15-1080-Techapp1.pdf). When 
reviewing serologic studies, the authors did not define a 
specific antibody titer threshold but relied on the choices 
made in individual studies; studies that inferred influenza 
virus infections based on low postepidemic hemagglutina-
tion-inhibition titers, such as 10 or 20, may lack specificity 
because some persons could have preexisting antibodies 
(3). Measurement error can also be a concern. The authors 
probably should have excluded such studies.
In another systematic review of the asymptomatic frac-
tion of influenza virus infections (4), we found that study de-
signs could explain a great deal of heterogeneity in the asymp-
tomatic fraction in studies such as outbreak investigations 
that used molecular testing to confirm influenza virus infec-
tions rather than serologic studies that used antibody titer 
measurements to indicate infections. Asymptomatic frac-
tions were higher in general, and much more heterogeneous, 
in studies that followed the latter approach.
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